IND Submission Requirements: A Practical Guide for Pharmaceutical Companies

IND Submission Requirements: A Practical Guide for Pharmaceutical Companies

IND submission requirements are essential for pharmaceutical companies seeking permission to begin clinical investigations of a new drug candidate in the United States. An Investigational New Drug (IND) application must be submitted to the US Food and Drug Administration (FDA) before a clinical investigation involving human subjects can commence. The application contains the scientific, clinical, and manufacturing information needed to support the proposed investigation and demonstrate that it can be conducted safely.

Understanding IND Submissions

An Investigational New Drug (IND) application enables a sponsor to seek FDA authorisation to administer an investigational drug to humans. It includes information about the drug’s composition, manufacturing process, non-clinical studies, and proposed clinical investigation. This information helps the FDA evaluate the scientific basis and safety considerations of the planned clinical trial.

Key Requirements

A typical IND application includes the following components:

Preclinical Study Data: Pharmacology and toxicology data supporting the proposed clinical investigation and providing relevant evidence about the investigational product’s safety.

Chemistry, Manufacturing and Controls (CMC): Information about the drug’s composition, manufacturing process, specifications, and quality control measures.

Clinical Protocol: Details of the proposed clinical trial, including its objectives, methods, study design, and participant eligibility criteria.

Investigator Information: Details of the investigator’s qualifications and other relevant information about the person responsible for conducting the clinical study.

Safety Information: Available evidence and information supporting the safe administration of the investigational product.

Importance of Proper Preparation

Meeting the IND submission requirements helps sponsors provide the FDA with complete and scientifically supported information. Incomplete documentation or inconsistencies may result in regulatory questions and additional review. Proper preparation also supports clinical trial planning and helps address participant safety considerations before the investigation begins.

Best Practices

Pharmaceutical companies should follow applicable FDA regulations, maintain accurate documentation, and coordinate closely with clinical and non-clinical teams. A thorough quality review should be completed before submission. Regulatory professionals should also ensure that the information across the application is consistent, complete, and supported by appropriate scientific evidence.

How MASUU Global Can Support

MASUU Global supports pharmaceutical companies with regulatory affairs activities, including regulatory documentation review, authoring, dossier compilation, and submission-related support. These services help organisations address regulatory documentation requirements, improve submission quality, and strengthen their regulatory readiness.

Understanding IND submission requirements is essential for preparing a well-organised and complete application for a clinical investigation. Careful planning, accurate documentation, and appropriate regulatory expertise help pharmaceutical companies navigate the IND submission process and establish a strong foundation for clinical development.

Book a Demo